94 recruiting, 77 completed, 29 not yet recruiting, 25 active not recruiting. 137 Phase 2, 99 Phase 1, 20 Early Phase 1, 11 Not applicable, 10 Phase 3.
Follow Psilocybin: new trials by email Literature Review of Psilocybin trials Research Report on Psilocybin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Profile of Psilocybin for Cocaine Use Disorder Psilocybin - Cocaine Use Disorder | Early Phase 1 | Suspended | University of California, Los Angeles | 10 | 2029-02-01 | 2026-04-07 |
| Psilocybin After Trauma Surgery for Pain Psilocybin (Usona Institute), Postoperative analgesia - Pain Management, Postoperative Pain | Phase 1 | Not yet recruiting | Trent Emerick | 70 | 2027-12-31 | 2026-08-06 |
| Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder Psilocybin - Opioid Use Disorder | Phase 2 | Withdrawn | Johns Hopkins University | 2027-04-01 | 2026-02-23 | |
| The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of Psilocybin 0mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink, 1mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink, 5mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink - Psilocybin Intoxication | Phase 1 | Not yet recruiting | Johns Hopkins University | 80 | 2027-03-01 | 2026-10-16 |
| Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder Psilocybin - Treatment Resistant Depression, Substance Use Disorders | Phase 1 / Phase 2 | Not yet recruiting | Indiana University | 50 | 2027-02-01 | 2026-10-23 |
| Psilocybin for Methamphetamine Use Disorder Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct)., Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions). - Methamphetamine Use Disorder | Phase 2 | Not yet recruiting | Peter Hendricks | 42 | 2027-02-01 | 2026-09-21 |
| Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study Psilocybin, Saline Placebo, Clonidine - Well-Being, Psychological, Psychedelic Experiences | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 120 | 2027-02-01 | 2026-10-30 |
| Psilocybin for Depression in Veterans Psilocybin, modafinil, zolpidem - Major Depression | Phase 2 | Not yet recruiting | VA Office of Research and Development | 150 | 2027-01-01 | 2026-10-26 |
| Group PACBT for Depression Psilocybin (drug), Group Cognitive Behavioral Therapy - Depression - Major Depressive Disorder, Psilocybin | Phase 2 | Not yet recruiting | University of California, Los Angeles | 30 | 2027-01-01 | 2026-05-04 |
| Effects of Psilocybin on Craving in Nicotine Dependence Psilocybin (drug) - Nicotine Dependence | Phase 2 | Not yet recruiting | University of British Columbia | 3 | 2027-01-01 | 2026-10-01 |
| Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies Transcranial Magnetic Stimulation, Psilocybin (drug), Neurofeedback - PTSD, PTSD - Post Traumatic Stress Disorder | Phase 2 | Not yet recruiting | University of New Mexico | 150 | 2026-12-31 | 2026-10-30 |
| Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg - Chronic Low Back Pain (CLBP), Physical Therapy | Phase 2 | Not yet recruiting | Yale University | 48 | 2026-12-01 | 2026-10-26 |
| ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder Psilocybin, Psilocybin-Assisted Therapy With Dialectical Behavior Therapy - Borderline Personality Disorder, Borderline Personality Pathology | Phase 1 | Not yet recruiting | University of Minnesota | 18 | 2026-12-01 | 2026-09-22 |
| Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life Psilocybin (Usona Institute) - Aging, Longevity | Phase 1 | Not yet recruiting | Charles Raison | 50 | 2026-12-01 | 2026-10-13 |
| Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder Psilocybin - Alcohol Use Disorder | Phase 2 | Not yet recruiting | Brigham and Women's Hospital | 36 | 2026-11-15 | 2026-10-09 |
| NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy Psilocybin (drug), Standard of Care (SOC) - Psilocybin, Neuropathy | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 83 | 2026-11-04 | 2026-10-05 |
| Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin Psilocybin, Cognitive Training - Alzheimer's Disease | Phase 2 | Recruiting | National Institute on Aging (NIA) | 200 | 2026-11-04 | 2026-10-30 |
| Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study Psilocybin (Usona Institute) - Chronic Pelvic Pain | Phase 1 | Recruiting | Oregon Health and Science University | 15 | 2026-11-01 | 2026-09-23 |
| Psilocybin Therapy for Methamphetamine Use Disorder and HIV Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support - Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV) | Phase 2 | Not yet recruiting | Nicky Mehtani, MD, MPH | 30 | 2026-11-01 | 2026-08-11 |
| Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation Psilocybin (Usona Institute), Inactive Placebo (Usona Institute) - Phase I | Phase 1 | Recruiting | Brown University | 24 | 2026-11-01 | 2026-10-08 |
Showing 20 of 263. Sign in to see all of them.
Depression (46) · Depressive Disorder, Major (32) · Depressive Disorder, Treatment-Resistant (26) · Stress Disorders, Post-Traumatic (22) · Alcoholism (19) · Anxiety Disorders (15) · Neoplasms (10) · Opioid-Related Disorders (9) · Obsessive-Compulsive Disorder (8) · Substance-Related Disorders (7) · Anorexia Nervosa (6) · Chronic Pain (6) · Depressive Disorder (6) · Pain (5) · Anhedonia (4)
Johns Hopkins University (28) · Yale University (14) · University of Wisconsin, Madison (9) · Centre for Addiction and Mental Health (8) · NYU Langone Health (8) · COMPASS Pathways (7) · University Hospital, Basel, Switzerland (6) · Imperial College London (5) · University of Calgary (5) · University of Washington (5) · University Health Network, Toronto (4) · University of California, Los Angeles (4) · University of Zurich (4) · Washington University School of Medicine (4) · Centre Hospitalier Universitaire de Nīmes (3)
United States (168) · Canada (34) · United Kingdom (15) · Switzerland (11) · Denmark (6) · France (6) · Ireland (4) · Sweden (4) · Czechia (3) · Germany (3) · Israel (3) · Netherlands (3) · Australia (2) · Belgium (2) · Brazil (2)
Charles Raison, MD (7) · Frederick S Barrett, PhD (4) · Roland R Griffiths, Ph.D. (4) · Anthony Back, MD (3) · Benjamin Kelmendi, MD (3) · Ishrat Husain, MBBS, MD (3) · Leah Mayo, PhD (3) · Michael Bogenschutz, MD (3) · Sandeep Nayak, MD (3) · Scott Aaronson, MD (3) · Alan K Davis, PhD (2) · Albert Garcia-Romeu, PhD (2) · Anders Fink-Jensen, Professor (2) · Anthony Bossis, PhD (2) · Christopher Nicholas, PhD (2)
PMID 17196053, PMID 20819978, PMID 21674151, PMID 24550805, PMID 25586396, PMID 27578767, PMID 27909164, PMID 27909165, PMID 28353056, PMID 28704354, PMID 29020861, PMID 29577509, PMID 29764303, PMID 29945469, PMID 31543078, PMID 31916890, PMID 32371500, PMID 33146667, PMID 33150319, PMID 33184743, PMID 33852780, PMID 33902087, PMID 33993135, PMID 34744825, PMID 34867525, PMID 35001856, PMID 35217796, PMID 35411074, PMID 35431912, PMID 36001306, PMID 36044208, PMID 36241352, PMID 36322843, PMID 36332827, PMID 36507738, PMID 36532184, PMID 36636296, PMID 36881769, PMID 37142308, PMID 37181888, PMID 37231080, PMID 37276086, PMID 37302533, PMID 37337526, PMID 37488291, PMID 37651119, PMID 38055270, PMID 38105655, PMID 38247730, PMID 38264632
2025 (2), R34AT013077 (2), 1DP2DA066200 (1), 1UG3DA062088-01 (1), 1UG3DA067126 (1), 2016 (1), 2017 (1), 2023 (1), I01RD001520 (1), K23MH122777 (1), P30CA138292 (1), R01AA031417 (1), R01DA066452 (1), R01MH142698 (1), R03DA042336 (1)